- Net income: DKK 20.05 billion (below estimate of DKK 22.64 billion)
- Gross margin: 84.9% (met estimate of 84.9%)
- Cash from operating activities: DKK 50.50 billion (exceeded estimate of DKK 32.28 billion)
- GLP-1 sales: DKK 37.04 billion (slightly below estimate of DKK 37.4 billion)
- Long-acting insulin sales: DKK 4.74 billion (above estimate of DKK 4.37 billion)
- Levemir sales: DKK 1.37 billion (significantly above estimate of DKK 752.1 million)
- NovoMix sales: DKK 1.27 billion (below estimate of DKK 1.35 billion)
- Fiasp sales: DKK 565 million (above estimate of DKK 525.4 million)
- Human insulin sales: DKK 1.57 billion (below estimate of DKK 1.81 billion)
- Diabetes & Obesity care sales: DKK 64.08 billion (slightly below estimate of DKK 64.62 billion)
- Haemophilia A unit sales: DKK 613 million
- NovoSeven sales: DKK 1.80 billion (slightly below estimate of DKK 1.82 billion)
- Company comments: Growth driven by increased demand for GLP-1-based treatments
- Analyst recommendations: 21 buys, 9 holds, 4 sells
A look at Novo Nordisk A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts predict a promising long-term outlook for Novo Nordisk A/S, a company specializing in pharmaceutical products with a focus on diabetes care. Smart Scores indicate strong potential in areas of Growth and Momentum, with scores of 4 each. This positions Novo Nordisk well for continued expansion and market performance.
Additionally, the company shows resilience with a score of 3, reflecting its ability to weather challenges. While Value and Dividend scores are moderate at 2, Novo Nordisk remains a key player in the pharmaceutical industry with a diverse product portfolio. With its strengths in growth and momentum, Novo Nordisk is poised for sustained success in the global market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
